Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis

Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance

(2011) C. Bourquin et al.   CANCER RESEARCH

Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats

(2011) Patricia J McLaughlin et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Imiquimod simultaneously induces autophagy and apoptosis in human basal cell carcinoma cells

(2010) S-W. Huang et al.   BRITISH JOURNAL OF DERMATOLOGY

Activation of TLR2 and TLR5 did not affect tumor progression of an oral squamous cell carcinoma, YD-10B cells

(2010) Jong-Hwan Park et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas

(2009) Camilla Rydberg et al.   IMMUNOLOGY

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Recent Advances in Head and Neck Cancer

(2008) Robert I. Haddad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival following primary surgery for oral cancer

(2008) Simon N Rogers et al.   ORAL ONCOLOGY